Adult genital psoriasis: An updated review for clinicians

Abstract

Genital psoriasis is a chronic inflammatory skin condition that has been reported in up to 63% of patients with psoriasis on other parts of their skin. It has a profound impact on quality of life and sexual function which is often overlooked by current severity scores. Despite its prevalence and disease burden, genital psoriasis remains largely under‐reported and under‐treated. Historically, this was due to the impracticality and limited efficacy data of standard psoriasis treatments when applied to genital skin. However, there have been recent advancements with several new agents currently being developed and evaluated for genital psoriasis. This clinical review aims to provide an overview of the current evidence regarding the clinical features of genital psoriasis, available management options and tools for assessing patients' quality of life. Key takeaways from this review emphasise the recognition of genital psoriasis as a chronic and debilitating condition, unique in its impact on patients' quality of life, necessitating sensitive and attentive approaches to address their needs.

Rapid progression of condyloma acuminatum caused by IL-17A antibody treatment: a case report

“…In this case, the patient has psoriasis in the genital area, a site of disease that is underrecognized and undertreated. Most systemic treatments for psoriasis may benefit patients with genital involvement, including secukinumab ( 4 ). Secukinumab treatment is effective in improving skin lesions in the scrotum of this patient.…”